Test Price
3,000 AED✅ Home Collection Available
Maturity-Onset Diabetes of the Young (MODY) Gene Panel in UAE | 3000 AED | DNA Labs UAE
Executive Summary & Core Metrics
- Diagnostic Accuracy: 99.9% analytical sensitivity via ISO 15189‑accredited next‑generation sequencing.
- Clinical Utility: Differentiates monogenic MODY from type 1 and type 2 diabetes, enabling targeted therapy and family cascade screening.
- Sample Collection: VIP Mobile Phlebotomy & temperature‑controlled cold‑chain home collection available daily 8 AM–11 PM across Dubai and the UAE.
- Post‑Test Support: Telephonic genetic counselling and expert result interpretation included with every report.
Direct Billing Verification
WhatsApp +971 54 548 8731
Test Overview & Methodology
The MODY Gene Panel uses next‑generation sequencing (NGS) to analyse the complete coding regions and splice sites of genes commonly associated with maturity‑onset diabetes of the young, including GCK, HNF1A, HNF4A, HNF1B, PDX1, NEUROD1, KLF11, CEL, PAX4, INS, BLK, KCNJ11, ABCC8, and APPL1. Each identified variant is classified according to ACMG/AMP guidelines and correlated with clinical phenotype to provide a definitive molecular diagnosis.
| Parameter | MODY Gene Panel (DNA Labs UAE) | Standard Biochemical Assessment |
|---|---|---|
| Diagnostic Precision | 99.9% analytical sensitivity; identifies all known MODY subtypes with clear variant classification | Indirect; cannot distinguish monogenic from polygenic aetiologies |
| Methodology | Next‑Generation Sequencing (NGS) – gold‑standard genomic analysis | Biochemical assays (fasting glucose, HbA1c, C‑peptide, autoantibodies) |
| Turnaround Time | 30 working days (comprehensive sequencing and variant interpretation) | Rapid (same day to 48 h), but non‑definitive for monogenic diabetes |
Physician Insight & Safety Protocols
“The MODY Gene Panel provides a definitive molecular diagnosis for patients presenting with young‑onset diabetes, a multi‑generational family history, or atypical metabolic features. Accurate subtype classification guides precise therapy—sulfonylureas for most HNF1A and HNF4A cases, and dietary management for GCK‑MODY—sparing patients from unnecessary insulin. I always emphasise that results must be interpreted in the full clinical context, and that a negative panel does not exclude all rare genetic causes. Our genetic counselling team is available to support patients and referring physicians throughout this process.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Medication Advisory
⚠️ Do not discontinue, adjust, or initiate any diabetes medication—including insulin, sulfonylureas, or oral hypoglycaemic agents—without direct consultation with your managing endocrinologist or primary care physician. Abrupt changes in therapy can lead to severe hypoglycaemia or hyperglycaemia.
Exclusion Criteria & ER Red Flags
- Sample‑Related Exclusions: Recent blood transfusion (within the past 4 weeks), active haemolysis, or insufficient blood volume may compromise sequencing quality and require recollection.
- Prenatal Sampling Note: Amniocentesis or chorionic villus sampling for prenatal MODY testing must be performed exclusively by a qualified maternal‑fetal medicine specialist in an accredited hospital setting.
- Emergency Warning Signs: Severe hypoglycaemia, hyperglycaemia accompanied by ketosis, altered consciousness, rapid unintentional weight loss, or symptoms of diabetic ketoacidosis while awaiting results require immediate evaluation at the nearest emergency department.
Patient FAQ & Clinical Guidance
1. What is the MODY Gene Panel, and how does it differ from a routine diabetes blood test?
The MODY Gene Panel is a molecular genetic test that directly identifies inherited mutations responsible for monogenic diabetes. Unlike standard glucose or HbA1c tests, which only measure metabolic control, this panel provides a definitive aetiological diagnosis. This distinction is critical because many MODY subtypes respond excellently to low‑dose sulfonylureas rather than insulin, and a positive result enables targeted cascade screening of at‑risk family members.
2. Who should consider this genetic test, and which clinicians typically order it?
Testing is recommended for individuals diagnosed with diabetes before age 35—particularly before age 25—who have a strong family history of diabetes spanning multiple generations, negative pancreatic autoantibodies, or atypical features such as absence of obesity or metabolic syndrome. Endocrinologists, diabetologists, clinical geneticists, and primary care physicians commonly order this panel and collaborate to interpret results and guide long‑term management.
3. How is the blood sample collected, and what home collection services are available in the UAE?
A certified phlebotomist collects a standard peripheral whole blood sample using sterile technique. DNA Labs UAE offers a VIP Mobile Phlebotomy and temperature‑controlled cold‑chain home collection service operating daily from 8 AM to 11 PM across Dubai and the UAE. This hospital‑grade service brings professional sample collection directly to your residence or office, with a typical arrival time of under 60 minutes from booking confirmation.
UAE Regulatory & Data Privacy Adherence
DNA Labs UAE operates under Dubai Healthcare City Authority (DHCA) registration and complies with all applicable UAE federal and local regulations governing in vitro diagnostics, medical laboratory practice, and patient data protection.
- Data Protection: All genetic and personal data are processed in strict accordance with Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL).
- Health Information Governance: Electronic health records and genomic data are managed under Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields.
- Clinical Safety Framework: Patient safety, informed consent, and medical liability standards are governed by Federal Decree‑Law No. 4 of 2016 on Medical Liability.
All laboratory processes are ISO 15189‑accredited, and results are released only to the requesting physician or authorised patient portal.
Clinical & Logistical Metadata
| Test Name | Maturity‑Onset Diabetes of the Young (MODY) Gene Panel |
| Price (AED) | 3,000 AED |
| Turnaround Time | 30 working days |
| Sample Type / Matrix | Whole Blood (peripheral) – 3–5 mL in EDTA tube. VIP Mobile Phlebotomy & temperature‑controlled cold‑chain home collection available daily 8 AM–11 PM. |
| Methodology Used | Next‑Generation Sequencing (NGS) on Illumina platform with Sanger confirmation for clinically significant variants |
| ICD‑10‑CM Code | E13.9 (Other specified diabetes mellitus without complications) |
| LOINC Code | 100004‑5 (MODY gene panel) |
| DHA Facility License & Laboratory Address | DHA Facility License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | Corporate Lab: DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians